


CLAIMS

1. An anhydrate crystalline form, which is Form 2 of compound of formula (1)



(1)

5, characterized by having a powder-X-ray diffractogram displaying peaks expressed as degree 2-Theta angles at about 9.5; 11.8; 14.1; 14.6; 17.7 and 18.5.

2. The anhydrate crystalline Form 2 of compound of formula (1) according to claim 1, having a powder-X-ray diffractogram comprising a peak expressed as degree 2-Theta angles at about 9.5.

10 **3.** The anhydrate crystalline Form 2 of compound of formula (1) according to claim 1 or claim 2, which further shows the following peaks expressed as degree 2-Theta angles: at about 15.5; 15.9; 16.6 and 22.2, optionally further characterized by a powder X-ray diffractogram as substantially illustrated in figure 1.

4. The anhydrate crystalline Form 2 of compound of formula (1) according to
15 anyone of claims 1 to 3, wherein a differential scanning calorimetry DSC shows a melting
endotherm at about 204°C onset, optionally further characterized by a thermogram as
substantially illustrated in figure 2.

5. The anhydrate crystalline Form 2 of compound of formula (1) according to anyone of claims 1 to 4, characterized by showing a weight gain of less than 0.2 weight %, in particular less than 0.1 weight %, based on the weight of the crystalline Form 2 anhydrate, as determined by Dynamic Vapor Sorption (DVS) in the range of from 0% to 95% relative humidity at a temperature of about 25°C, optionally further characterized by a DVS isotherm plot as substantially shown in figure 3.

6. A solid form, which is anhydrate crystalline Form 2 of the compound of formula (1) according to anyone of claims 1 to 5.

7. Process for the preparation of the anhydrate crystalline Form 2 of compound of formula (1) as defined in anyone of claims 1 to 5, comprising at least the following
5 steps:

- 1) solubilizing the compound of formula (1) in amorphous form in a solvent selected from alcohols, ketones, acetates, ethers and acetonitrile, optionally in admixture with water, at a set temperature ranging from 18°C to 80°C;
- 2) leaving the solution obtained in step 1) at the same temperature as the one set in step 1)
10 for almost complete evaporation;
- 3) isolating the anhydrate crystalline Form 2 of compound of formula (1) formed in step 2).

8. The process according to claim 7, wherein the solvent is selected from methanol, methanol/water mixture, ethanol, ethanol/water mixture, 2-propanol, 1-propanol, 1-propanol/water mixture, 1-butanol, 1-butanol/water mixture, acetone, acetone/water
15 mixture, 2-butanone, 2-butanone/water mixture, methyl isobutyl ketone, methyl isobutyl ketone/water mixture, methyl acetate, methyl acetate/water mixture, ethyl acetate, ethyl acetate/water mixture, isopropyl acetate, isopropyl acetate/water mixture, isobutyl acetate, isobutyl acetate/water mixture, acetonitrile, and methyl tert-butyl ether.

9. The process according to claim 7 or 8, wherein the set temperature of step 1)
20 and step 2) is selected from a range of temperature from 20°C to 80°C, or even from 25°C to 80°C.

10. Process for the preparation of the anhydrate crystalline Form 2 of compound of formula (1) as defined in anyone of claims 1 to 5, comprising at least the following steps:

- 25 1) solubilizing or suspending the compound of formula (1) in amorphous form in a solvent selected from alcohols, ketones, acetates, ethers and acetonitrile, at a set temperature which is room temperature;
- 2) optionally purifying the solution or suspension obtained in step 1) by heating at a set temperature ranging from 60°C to 80 °C, stirring and filtering the solution or suspension;
- 30 3) heating the solution or suspension obtained in step 1) or in step 2) at a set temperature ranging from 60°C to 80°C;

4) cooling the solution or suspension obtained in step 2) to a set temperature ranging from -20°C to 25°C;

5) isolating the anhydrate crystalline Form 2 of compound of formula (1) formed in step 4).

11. The process according to claim 10, wherein the solvent is selected from ethanol, 2-propanol, 1-propanol, 1-butanol, acetone, 2-butanone, methyl isobutyl ketone, isopentyl methyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, isobutyl acetate, acetonitrile, and methyl tert-butyl ether.

12. Process for the preparation of the anhydrate crystalline Form 2 of compound of formula (1) as defined in anyone of claims 1 to 5, comprising at least the following steps:

1) solubilizing or suspending the compound of formula (1) in amorphous form in a solvent selected from alcohols, ketones, acetates, and diethyl-ether, at a set temperature which is room temperature;

2) optionally filtering the solution or suspension obtained in step 1);

3) adding water as a non-solvent;

4) isolating the anhydrate crystalline Form 2 of compound of formula (1) formed in step 3).

13. The process according to claim 12, wherein the solvent is selected from 2-propanol, 1-propanol, 1-butanol, acetone, 2-butanone, methyl isobutyl ketone, isopentyl methyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, isobutyl acetate, and diethyl ether.

14. Process for the preparation of the anhydrate crystalline Form 2 of compound of formula (1) as defined in anyone of claims 1 to 5, comprising at least the following steps:

1) solubilizing or suspending the compound of formula (1) in amorphous form in a solvent selected from alcohols, ketones, and acetates, at a set temperature which is room temperature;

2) optionally filtering the solution or suspension obtained in step 1);

3) adding heptane as a non-solvent;

4) isolating the anhydrate crystalline Form 2 of compound of formula (1) formed in step 3).

15. The process according to claim 14, wherein the solvent is selected from ethanol, 2-propanol, 1-propanol, 1-butanol, acetone, 2-butanone, methyl isobutyl ketone,

isopentyl methyl ketone, methyl acetate, ethyl acetate, isopropyl acetate, and isobutyl acetate.

16. Process for the preparation of the anhydrate crystalline Form 2 of compound of formula (1) as defined in anyone of claims 1 to 5, comprising at least the following steps:

1) solubilizing or suspending the compound of formula (1) in amorphous form in an organic solvent;

2) adding seeds of anhydrate crystalline Form 2 of the compound of formula (1).

17. The process according to claim 16, wherein steps 1) and 2) are followed by the step of adding a non-solvent, then performing distillation, followed by cooling and drying.

18. A medicament, characterized in that it comprises the anhydrate crystalline Form 2 of compound of formula (1) as defined in anyone of claims 1 to 5.

19. Pharmaceutical composition comprising the anhydrate crystalline Form 2 of compound of formula (1) as defined in anyone of claims 1 to 5, and at least one pharmaceutically acceptable excipient.

20. The pharmaceutical composition according to claim 19, wherein said anhydrate crystalline form 2 is substantially pure and substantially free of alternative forms.

21. The pharmaceutical composition according to claim 19, wherein said anhydrate crystalline form 2 is at least 90 percent by weight of all forms.

22. The anhydrate crystalline Form 2 of compound of formula (1) as defined in anyone of claims 1 to 5 for use as a medicine.

23. The anhydrate crystalline Form 2 of compound of formula (1) as defined in anyone of claims 1 to 5 for use in the treatment of cancer.